Tempramed's Vivi Cap evaluated for summer travel use

Executive Summary

• Tempramed Technologies announced the publication of a clinical case report in the Journal of Clinical & Medical Case Reports validating the use of its Vivi Cap device for passive thermal protection of insulin during extreme heat.
• The publication reinforces the company's independently validated payer ROI model, linking clinical stability (glycemic control) with economic benefits (reduced medication wastage and emergency care utilization).
• Management views this scientific evidence as a critical catalyst for expanding payer coverage and reimbursement discussions for Vivi Cap.

Key Details

• Publication Details:
  • Title: "Passive Thermal Protection of In-Use Insulin During Summer Travel: Device Description and Single-Patient Case Report with a Simple Cost Perspective."
  • Authors: Prof. Andreas Pfutzner (Tempramed’s Medical Director) and colleagues.
  • Journal: Journal of Clinical & Medical Case Reports.
  • Date: February 2026.
• Clinical Case Study Results (Patient with Type 1 Diabetes in Greece, 35-38°C):
  • Improved Time in Range: 86% (with Vivi Cap) vs. 82% (without thermal protection).
  • Reduced Time Above 250 mg/dL: 3% (with Vivi Cap) vs. 5% (without thermal protection).
  • Stable mealtime insulin requirements despite extreme heat.
  • Zero emergency department or urgent care visits.
  • Reported reduction in patient anxiety and increased confidence in insulin effectiveness.
• Economic & Payer Validation:
  • The publication explicitly references Tempramed’s independently validated payer return-on-investment (ROI) model.
  • Primary economic drivers identified: Prevention of medication wastage due to temperature excursions, avoidance of heat-related glycemic deterioration, reduction in severe hyperglycemia/diabetic ketoacidosis events, and lower anxiety-driven healthcare utilization.
  • Validation Status: The payer savings model received third-party validation by the Validation Institute through January 2027.
• Strategic Implications:
  • Management describes the publication as a bridge between clinical plausibility and health-economic validation.
  • The company is leveraging this data to support pilot programs and coverage decisions with various payers.
  • Goal: Position Vivi Cap as a reimbursable, cost-saving standard in diabetes management and other temperature-sensitive therapies.

Notable Quotes

• "This publication provides scientific context to the economic case we have already validated. It highlights how thermal protection can translate into clinical stability and patient confidence in high-risk environments -- exactly the drivers incorporated into our validated payer ROI model. Together, clinical rationale and economic validation significantly strengthen our reimbursement discussions." — Ron Nagar, Chief Executive Officer of Tempramed.